Wire · opportunities
Biocurious: It's spring, when a young man's fancy lightly turns to … clinical trial results
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Late-stage clinical trial results from Australian biotech firms Paradigm Biopharmaceuticals, Recce Pharmaceuticals, and Actinogen Medical are imminent, determining their future valuation and market positions. Paradigm's knee osteoarthritis trial interim results are due imminently, while Recce's antibiotic trial results in Indonesia and Australia are expected by late 2027 or early 2028. Actinogen also contemplates a depression trial as a contingency.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup faces a defining moment as trial results either unlock investment and market access or close doors. Dial in now on interim data and regulatory pathways to seize early wins or pivot fast with backup plans like Actinogen's depression study.
◆ Coverage
1 source · 2 Sep 2026
◆ Related on Wire
◆ Topics